Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200280224> ?p ?o ?g. }
- W3200280224 abstract "Introduction In the past, targeted therapies have not shown positive results as they have been used without adequate molecular selection of patients with biliary tract cancer (BTC). This has led to an expansion of research on characteristics and molecular selection to identify new effective strategies in this setting. Improved knowledge of the molecular biology of these neoplasms has highlighted their extraordinary heterogeneity and has made it possible to identify targetable gene alterations, including fibroblast growth factor receptor (FGFR) 2 gene fusions, and isocitrate dehydrogenase (IDH) mutations. The FDA recently approved ivosidenib and pemigatinib for the treatment of BTCs.Areas covered We review data in the literature regarding targeted therapies for the treatment of BTCs, as well as on the prospects deriving from the extraordinary molecular heterogeneity of these neoplasms.Expert opinion At present, it is essential to evaluate the expression of the genetic alterations expressed by these neoplasms to offer patients an increasingly personalized therapeutic approach. Studies are needed to better define the limits and potentials of targeted therapies and their role in the therapeutic algorithm to improve the poor prognosis of these patients." @default.
- W3200280224 created "2021-09-27" @default.
- W3200280224 creator A5003848263 @default.
- W3200280224 creator A5007635105 @default.
- W3200280224 creator A5012233597 @default.
- W3200280224 creator A5017926586 @default.
- W3200280224 creator A5020767180 @default.
- W3200280224 creator A5033188581 @default.
- W3200280224 creator A5033536074 @default.
- W3200280224 creator A5034035272 @default.
- W3200280224 creator A5037658807 @default.
- W3200280224 creator A5040416952 @default.
- W3200280224 creator A5048129292 @default.
- W3200280224 creator A5056023187 @default.
- W3200280224 creator A5063263109 @default.
- W3200280224 creator A5076563915 @default.
- W3200280224 creator A5076940330 @default.
- W3200280224 creator A5080291428 @default.
- W3200280224 date "2021-09-23" @default.
- W3200280224 modified "2023-09-23" @default.
- W3200280224 title "Molecular-driven treatment for biliary tract cancer: the promising turning point" @default.
- W3200280224 cites W1586218645 @default.
- W3200280224 cites W180914436 @default.
- W3200280224 cites W1903979702 @default.
- W3200280224 cites W1949964307 @default.
- W3200280224 cites W1960850967 @default.
- W3200280224 cites W1964321121 @default.
- W3200280224 cites W1974564771 @default.
- W3200280224 cites W1988476050 @default.
- W3200280224 cites W2007555374 @default.
- W3200280224 cites W2008777301 @default.
- W3200280224 cites W2009447162 @default.
- W3200280224 cites W2012887353 @default.
- W3200280224 cites W2015116101 @default.
- W3200280224 cites W2015613033 @default.
- W3200280224 cites W2017452957 @default.
- W3200280224 cites W2018041848 @default.
- W3200280224 cites W2019397580 @default.
- W3200280224 cites W2025130792 @default.
- W3200280224 cites W2039614598 @default.
- W3200280224 cites W2052205828 @default.
- W3200280224 cites W2053954823 @default.
- W3200280224 cites W2058770031 @default.
- W3200280224 cites W2062138514 @default.
- W3200280224 cites W2063432158 @default.
- W3200280224 cites W2072564984 @default.
- W3200280224 cites W2073597876 @default.
- W3200280224 cites W2081990599 @default.
- W3200280224 cites W2090446824 @default.
- W3200280224 cites W2096796171 @default.
- W3200280224 cites W2107977954 @default.
- W3200280224 cites W2112950772 @default.
- W3200280224 cites W2113222623 @default.
- W3200280224 cites W2125079553 @default.
- W3200280224 cites W2131796349 @default.
- W3200280224 cites W2133575075 @default.
- W3200280224 cites W2136629154 @default.
- W3200280224 cites W2141042450 @default.
- W3200280224 cites W2143688993 @default.
- W3200280224 cites W2146934263 @default.
- W3200280224 cites W2151660860 @default.
- W3200280224 cites W2157232767 @default.
- W3200280224 cites W2161608625 @default.
- W3200280224 cites W2164277652 @default.
- W3200280224 cites W2269736158 @default.
- W3200280224 cites W2310278114 @default.
- W3200280224 cites W2325900794 @default.
- W3200280224 cites W2335155752 @default.
- W3200280224 cites W2340909673 @default.
- W3200280224 cites W2395507246 @default.
- W3200280224 cites W2408652783 @default.
- W3200280224 cites W2510836133 @default.
- W3200280224 cites W2520639290 @default.
- W3200280224 cites W2520734402 @default.
- W3200280224 cites W2554089088 @default.
- W3200280224 cites W2564810646 @default.
- W3200280224 cites W2566505805 @default.
- W3200280224 cites W2566575334 @default.
- W3200280224 cites W257954806 @default.
- W3200280224 cites W2589651021 @default.
- W3200280224 cites W2601520864 @default.
- W3200280224 cites W2603694770 @default.
- W3200280224 cites W2608084876 @default.
- W3200280224 cites W2618618401 @default.
- W3200280224 cites W2627067328 @default.
- W3200280224 cites W2724543993 @default.
- W3200280224 cites W2737813521 @default.
- W3200280224 cites W2745824859 @default.
- W3200280224 cites W2769183729 @default.
- W3200280224 cites W2769909737 @default.
- W3200280224 cites W2781885238 @default.
- W3200280224 cites W2782564608 @default.
- W3200280224 cites W2789914600 @default.
- W3200280224 cites W2796668941 @default.
- W3200280224 cites W2799610897 @default.
- W3200280224 cites W2806800293 @default.
- W3200280224 cites W2809204032 @default.
- W3200280224 cites W2883507417 @default.
- W3200280224 cites W2887948931 @default.
- W3200280224 cites W2889657308 @default.